Acute Myeloid Leukemia (AML)
Conditions
Keywords
Acute myeloid leukemia,, midostaurin,, healthcare resource utilization
Brief summary
This was a non-interventional, retrospective registry study, utilizing electronic health record (EHR) data collected in the hospital district of Helsinki and Uusimaa (HUS). Real-world health care resource utilization (HCRU) of AML patients was characterized.
Detailed description
Adult patients (18 years or older) with the inclusion diagnosis, AML (ICD-10 C92.0), between 1.1.2013 - 30.6.2020 were followed from the index date (first ever record of the inclusion diagnosis) until the end of follow-up (30.6.2020), or death. This study did not involve any contacts to patients. The study inclusion period was changed from 1.1.2013 - 30.6.2020 specified in the protocol to 1.1.2016 - 30.6.2020 due to lack of medication data from pre-2016.
Interventions
DRUGMidostaurin
Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patients who are diagnosed with acute myeloid leukemia (ICD-10 C92.0) during 1.1.2016-30.6.2020 * Adult (18 years or older) at the time of first diagnosis * Health registry data is available and accessible * Resident in the hospital district HUS at the time of index diagnosis
Exclusion criteria
\- AML patients with no treatment information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients initiating midostaurin treatment | throughout the study, approximately 5 years | Number of patients initiating midostaurin treatment were reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Midostaurin at induction and consolidation phase | throughout the study, approximately 5 years | Duration of Midostaurin at induction and consolidation phase were reported. |
| Median average dose intensity in midostaurin treatment in induction and consolidation phase | throughout the study, approximately 5 years | Median average dose intensity in midostaurin treatment were reported. |
| Most frequent comorbidities at the time of AML diagnosis | throughout the study, approximately 5 years | Most frequent comorbidities at the time of AML diagnosis were reported. |
| Number of patients who received Midostaurin at induction and consolidation phases | throughout the study, approximately 5 years | Number of patients who received Midostaurin at induction and consolidation phases were reported. |
| Number of AML patients receiving midostaurin consolidation treatment in inpatient or outpatient care (based on given prescriptions) | throughout the study, approximately 5 years | Number of AML patients receiving midostaurin consolidation treatment in inpatient or outpatient care (based on given prescriptions) were reported. |
| Mean HCRU and related costs in different disease stages | throughout the study, approximately 5 years | Estimate HCRU and related costs in different disease stages were reported. |
| Number of patients at the time of diagnosis (All treated AML patients) | throughout the study, approximately 5 years | Number of patients at the time of diagnosis (All treated AML patients) were reported. |
Countries
Finland
Outcome results
None listed